ACT Masters representative crews announced

,

ACT Masters representative crews announced

RACT’s committee has ratified the following crews to represent the ACT at the Rowing Australia Masters Championship regatta at Ballarat on 26 May, 2012.

Women’s EIGHT:
cox Anne Whelan
str Anita Preiner
7 Elaine Bissaker
6 Kath Welman
5 Susan Linacre
4 Anne Charlton
3 Amanda Brian
2 Judi Walsh
bow Margie Pentony

Women’s QUAD:
Str Emy Ayliffe
3 Selina Rowland
2 Evelyn Sommer
Bow Judi Walsh

Mens EIGHT:
cox Rebecca McCallum
Str Mark Partridge
7 Scott Pagan
6 Scott Waller
5 Damien Pentony
4 Geoff Brown
3 Martin Little
2 Charles Huxtable
Bow Michael Clifford

Mens Quad:
Str Steve Mirtschin
3 Kym Fisher
2 Andy Horsburgh
bow Peter Laidlaw

We wish these crews the best of racing in beautiful Ballarat

10 replies
  1. valley
    valley says:

    The side effects associated with CJC 1295 and Ipamorelin can vary depending on the dosage,
    frequency of use, individual physiology, and
    whether they are taken alone or in combination with other peptides.

    While many users report minimal adverse reactions, it is important to be aware of both common and
    rare potential risks.

    A Closer Look at the Combination of CJC 1295 and Ipamorelin

    When used together, CJC 1295 and Ipamorelin act synergistically to stimulate growth
    hormone release. The combination can lead to a higher overall
    secretion of growth hormone compared with either peptide alone.

    However, the amplified effect may also increase the likelihood of side effects such as edema, joint pain, and insulin resistance.
    Some users have noted that the combined therapy produces more pronounced swelling around injection sites, especially
    when injections are administered in high volumes or at multiple sites per session.

    Introduction to CJC 1295 and Ipamorelin

    CJC 1295 is a synthetic growth hormone‑releasing peptide that binds to the ghrelin receptor, prolonging its activity by inhibiting degradation.
    It typically has a half‑life of about ten hours when combined
    with an antagonist such as CJC 1295 DAC. In contrast, Ipamorelin is a smaller peptide
    that selectively stimulates growth hormone release without affecting prolactin or cortisol levels.
    Because Ipamorelin has a shorter half‑life—around thirty minutes—it
    is often used in tandem with CJC 1295 to provide an initial surge followed by sustained stimulation.

    Common side effects of each peptide include local injection site reactions such as
    redness, itching, and mild pain. Systemic symptoms can involve headaches, dizziness, flushing, and transient changes in blood sugar levels.
    Users sometimes experience numbness or tingling in the extremities, which may be a sign of peripheral neuropathy if prolonged.

    Less frequent but notable adverse effects include fluid retention leading to edema in the ankles, feet, or face.
    This swelling is usually mild but can become uncomfortable or interfere with daily activities.

    Joint discomfort and stiffness are also reported, especially
    during periods of rapid growth hormone surges that affect cartilage metabolism.

    Metabolic impacts are a significant concern. Both peptides influence
    insulin sensitivity; some users have observed increased blood glucose readings following
    injections. In susceptible individuals, this may exacerbate pre‑existing
    conditions such as diabetes or prediabetes. Regular monitoring of fasting glucose
    and HbA1c levels is recommended for anyone on long‑term therapy.

    Hormonal balance can be affected over extended periods.
    Growth hormone excess may lead to acromegaly‑like symptoms in rare cases, including enlarged hands and feet, jaw protrusion, and facial changes.
    Hormone panels should be checked periodically to detect any abnormal elevations of growth hormone or
    its downstream mediator, insulin‑like growth factor 1.

    Immune reactions are uncommon but possible. Some users have reported mild allergic responses such as hives or itching
    after injections. In rare instances, more severe anaphylactic reactions
    may occur, necessitating immediate medical attention and the presence of emergency medication.

    The risk of developing antibodies against
    peptide therapy is low but cannot be entirely ruled out.
    Antibody formation could diminish efficacy over time and
    potentially cause immune‑mediated side effects.

    Psychological or behavioral changes are rarely documented.
    However, growth hormone can influence mood and energy levels; some users report increased irritability or mood swings during the initial weeks
    of therapy.

    Understanding Peptide Therapy

    Peptide therapy involves administering short chains of amino acids to target specific receptors in the body.
    Unlike traditional pharmaceuticals that often act systemically, peptides tend to have more
    selective actions due to their size and structure. Their mechanisms of action are typically well‑defined:
    CJC 1295 stimulates growth hormone secretion by mimicking
    natural ghrelin signals, while Ipamorelin triggers release
    through a distinct receptor pathway.

    Because peptides are biologically derived molecules, they can be broken down quickly in the bloodstream.

    This property necessitates careful dosing schedules to maintain therapeutic levels without causing spikes that might
    lead to side effects. Many clinicians recommend staggered injections or continuous infusion pumps
    for patients requiring stable hormone concentrations.

    Monitoring is a key component of peptide therapy. Baseline measurements of
    growth hormone, insulin‑like growth factor 1, thyroid hormones, and blood sugar should be established before starting treatment.
    Follow‑up labs are usually scheduled every few months to assess both efficacy
    and safety. Side effect profiles can shift over time; for example, mild edema may develop after several weeks even if initial injections were well tolerated.

    Patient education is also critical. Individuals should be instructed on proper injection techniques, storage conditions for
    peptides (often requiring refrigeration), and signs of adverse reactions that warrant medical
    evaluation. Recognizing early symptoms such as sudden swelling,
    joint pain, or unexplained changes in blood glucose
    can prevent more serious complications.

    In summary, while CJC 1295 and Ipamorelin are generally considered safe
    when used appropriately, users must remain vigilant
    for a range of potential side effects—from local injection reactions to systemic
    metabolic disturbances. Regular monitoring,
    dose adjustment, and open communication with a healthcare professional can help mitigate risks
    and ensure that peptide therapy delivers its intended benefits without undue harm.

    References:

    valley

Comments are closed.